Karam C. Mounzer, MD
Clinical Professor of Medicine (Infectious Diseases)
Attending Physician, Penn Presbyterian Medical Center
Department: Medicine
Contact information
Philadelphia Fight
1233 Locust Street
Philadelphia, PA 19107
1233 Locust Street
Philadelphia, PA 19107
Office: 215-790-1788
Fax: 215-732-5490
Fax: 215-732-5490
Email:
mounzerk@fight.org
mounzerk@fight.org
Education:
Bachelor (Experimental Sciences and French Literature)
College Notre Dame de Jamhour, Beirut, Lebanon, 1985.
MD (Pre-Med & Med combined)
Saint Joseph University, Faculty of Medicine, Beirut, Lebanon , 1992.
Permanent linkBachelor (Experimental Sciences and French Literature)
College Notre Dame de Jamhour, Beirut, Lebanon, 1985.
MD (Pre-Med & Med combined)
Saint Joseph University, Faculty of Medicine, Beirut, Lebanon , 1992.
Description of Research Expertise
Clinical Development of new antiretroviral agentsDescription of Clinical Expertise
Treatment of Multi drug Resistant HIV virus, HIV-HCV co-infectionDescription of Other Expertise
Suboxone Clinic for HIV infected opioid-addicted patientsSelected Publications
Dieterich DT, Brunet L, Hsu RK, Mounzer K, Pierone G Jr, Wohlfeiler MB, Fusco JS, Dunbar MS, Gruber J, Yee LJ, Frenette C, Lim T, Fusco GP. : . Monitoring and risk of hepatitis B reactivation and hepatitis flare during tenofovir interruption among people with HIV and hepatitis B. AIDS Jan 2026.Isobel McEwen1 , Gayathri Sridhar2 , Richard Elion1 , Leigh Ragone3 , Annemiek De Ruiter2 , Michael Aboud2 , Jean van Wyk4 , Kenneth Mayer5 , Karam Mounzer6 , Moti N. Ramgopal7 , Vani Vannappagari2: Long-Term Use, HIV Testing & Effectiveness in Individuals on CAB LA PrEP in the Trio Health Cohort. CROI 2026 2026.
Laurence Brunet1 , Steven K. Barnett2 , Jennifer Fusco3 , Karam Mounzer4 , Kevin R. Frost5 , Supriya Sarkar6 , Kimberley Brown7 , Harmony P. Garges7 , Vani Vannappagari7 , Gregory P. Fusco3: Comparing PrEP Coverage and HIV Acquisition Between CAB LA and Oral PrEP in the OPERA Cohort. CROI 2026 2026.
Douglas T. Dieterich1 , Laurence Brunet2 , Ricky K. Hsu3 , Karam Mounzer4 , Gerald Pierone5 , Michael B. Wohlfeiler6 , Rachel P. Weber7 , Jennifer Fusco7 , Cassidy Henegar8 , Vani Vannappagari9 , Kimberley Brown9 , Nassrin Payvandi8 , Gregory P. Fusco7: HIV-HBV Coinfection and Long-Acting Cabotegravir + Rilpivirine in the US: HBV and HIV Outcomes. CROI 2026 2026.
Malcolm Hedgcock1 , Mark Bloch2 , Jihad Slim3 , Moti N. Ramgopal4 , Jorge L. Santana5 , Xu Zhang6 , Jairo M. Montezuma-Rusca6 , Peter Sklar6 , Karam Mounzer7: Switch to BIC+LEN in Virologically Suppressed People With HIV on Complex Regimens: Week 96 Outcomes. CROI 2026 2026.
Mohammed Zogheib1 , John Koethe2 , Karam Mounzer3 , John J. Carr2 , James G. Terry2 , Sangeeta Nair2 , Jordan Lake4 , Colleen McGary1: Presence of Excess Visceral Abdominal Fat Impacts MASLD in People With HIV. CROI 2026 2026.
Laurence Brunet1 , Ricky K. Hsu2 , Anthony Mills3 , Kevin R. Frost4 , Gerald Pierone5 , Michael Sension6 , Philip C. Lackey7 , Karam Mounzer8 , Michael B. Wohlfeiler9 , Jennifer Fusco10, Michael Aboud11, Piotr Budnik12, Adrienne Guignard13, Vani Vannappagari11, Gregory P. Fusco10: Cabotegravir LA for PrEP: Progress in HIV Prevention From 3 Years of OPERA Data CROI 2026 2026.
Chloe M. Orkin1 , Peter J. Ruane2 , Malcolm Hedgcock3 , Cyril Gaultier4 , Marcelo Losso5 , Mark Bloch6 , Karam Mounzer7 , Hung-Chin Tsai8 , Kwanza Price9 , Keith Aizen9 , Martin Rhee9 , Xu Zhang9 , Jairo M. Montezuma-Rusca9 , Peter Sklar9 , Pedro Cahn10: Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1. CROI 2026 2026.
. Wei Y, Ma HK, Wong ME, Back H, Papasavvas E, Mounzer K, Aberra F, Morgenstern R , Tebas P, Konnikova L, Montaner LJ, Ho YC. : Transcription factor BACH2 shapes tissue-resident memory T cell programs to promote HIV-1 persistence. I Immunity Nov 2025.
. Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Aizen K, Zhang X, Sklar P, Montezuma-Rusca JM, Segal-Maurer S : . Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. Open Forum Infect Dis Oct 2025.